Cameron is a member of T-CURX’ scientific advisory board. He is a haemato-oncologist and Professor and Chair of Cancer Immunotherapy at the University of Sydney, Australia, and an international expert in the genetic engineering of immune T cells to fight hematologic malignancies.

Cameron obtained his M.B.B.S. (medical) degree from the University of Sydney in 1993. He was admitted in 2000 as a Fellow of the Royal Australasian College of Physicians (F.R.A.C.P.) and as a Fellow of the Royal College of Pathologists of Australasia (F.R.C.P.A.). He received a PhD from the University of Queensland, Brisbane, Australia in 2005.

He then did a postdoctoral research fellowship at Fred Hutchinson Cancer Center (FHCC) in Seattle, WA, USA. He spent 17 years with FHCC and was Professor and Anderson Family Endowed Chair for Immunotherapy at FHCC, Professor of Medicine at the University of Washington, and Co-Director of the Cancer Immunology Program of the Seattle Cancer Consortium until 2022, when he returned to Sydney, Australia, to develop a new program in Cancer Immunotherapy at the University of Sydney.

Cameron's research laboratory is focused on developing new cancer immunotherapies by defining the factors that impact outcomes of CAR-T cell therapies for cancer. He is author of more than 100 peer-reviewed publications in the field of cancer and immunotherapy.

Cameron has chaired cell therapy committees for the American Society of Hematology and the Center for International Bone Marrow Transplant Research, and is an elected member of the American Society for Clinical Investigation.